Skip to content

FDA Approves LYTENAVA for Wet AMD

Outlook Therapeutics secures FDA approval for LYTENAVA in wet AMD.

Outlook Therapeutics has received US Food and Drug Administration (FDA) approval for LYTENAVAโ„ข (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration, commonly known as wet AMD. The decision represents a significant clinical, regulatory and commercial milestone. LYTENAVA is the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the United States, giving retina specialists access to a formulation developed specifically for administration in the eye. It also concludes a regulatory journey lasting more than four years. Outlook Therapeutics now faces its next challenge: building access, supporting adoption and establishing a specialist commercial presence across the US retina market.

LYTENAVA FDA approval: the key facts.

  • The FDA approved LYTENAVA for patients with neovascular, or wet, age-related macular degeneration on 24 July 2026.
  • It is the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the United States.
  • The approved US presentation is 1.25 mg (25 mg/mL) in a single-dose vial.
  • Outlook Therapeutics expects to make LYTENAVA available to eligible US patients before the end of 2026.
  • Commercial preparations include reimbursement and patient-support programmes, physician support and the development of a specialist retina commercial organisation.
  • LYTENAVA is also authorised in the European Union and the United Kingdom, with commercial launches underway in Germany, Austria and the UK.

What is LYTENAVA?

LYTENAVA is an ophthalmic formulation of bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor. It works by binding to VEGF-A and limiting the abnormal blood-vessel growth and vascular leakage associated with wet AMD. Bevacizumab has played an established role in retina care for many years. However, ophthalmologists in the United States have historically used compounded preparations of bevacizumab off-label, as the medicine was originally developed and approved for intravenous use in oncology rather than as an ophthalmic product.LYTENAVA changes that regulatory position. It has been developed specifically for intravitreal administration and is supported by FDA-approved labelling, validated manufacturing processes, quality systems and ongoing pharmacovigilance. This distinction is central to the significance of the approval. It does not remove other anti-VEGF options from the treatment landscape, but it gives clinicians an FDA-approved ophthalmic bevacizumab option for the first time.

Why the approval matters for wet AMD care.

Wet AMD is a chronic retinal disease and a leading cause of severe vision loss among older adults. Treatment commonly involves repeated intravitreal injections over an extended period, placing continued emphasis on clinical efficacy, product consistency, quality and reliable access. The approval of LYTENAVA introduces an authorised formulation of a molecule already familiar to retina specialists. For clinicians and healthcare providers, its arrival could influence treatment protocols, procurement decisions, reimbursement pathways and conversations about the role of compounded medicines in retinal practice. In practice, its impact will depend not only on regulatory approval, but also on pricing, reimbursement, real-world adoption and integration into established clinical workflows.

A regulatory journey spanning more than four years.

The FDA decision follows an unusually persistent regulatory process for Outlook Therapeutics. The company first submitted a Biologics License Application for LYTENAVA in March 2022. It subsequently received three Complete Response Letters, issued in August 2023, August 2025 and December 2025. In 2026, Outlook pursued the FDA's Formal Dispute Resolution process. Its appeal was accepted in April and granted in May, after the Office of New Drugs concluded that substantial evidence of effectiveness had been established for bevacizumab-vikg in neovascular AMD. The FDA approval letter records Outlook's complete resubmission as 29 May 2026, leading to approval on 24 July. In summary, this outcome highlights the importance of regulatory strategy, clinical evidence and organisational resilience when bringing a new ophthalmic therapy to market.

From FDA approval to US commercial launch.

With approval secured, Outlook Therapeutics is now moving into commercial execution. The company expects LYTENAVA to become available to eligible US patients before the end of 2026. Its stated launch priorities include expanding reimbursement and patient-support access, supporting physicians nationwide and building a specialised retina commercial organisation. That transition creates a different set of organisational requirements. Regulatory approval must now be translated into market access, clinician engagement and consistent delivery. Success is likely to depend on experienced leadership and specialist talent across:

  • Retina sales and commercial leadership
  • Market access and reimbursement
  • Medical affairs and clinical education
  • Patient-support services
  • Commercial operations and launch strategy

For the wider ophthalmology sector, the launch will provide another example of how companies must align clinical evidence, regulatory progress and commercial capability to achieve meaningful adoption.

LYTENAVA in Europe and the UK.

LYTENAVA has already received centralised marketing authorisation from the European Commission and authorisation from the UK's Medicines and Healthcare products Regulatory Agency for the treatment of wet AMD. Commercial launches are underway in Germany, Austria and the United Kingdom. In some EU member states, country-level pricing and reimbursement approvals will still be required before the treatment can be sold. This growing international footprint allows Outlook Therapeutics to build a broader ophthalmology franchise while navigating the different market-access and reimbursement requirements of the US, UK and European markets.

What comes next for Outlook Therapeutics?

FDA approval is a defining milestone, but the next stage will determine LYTENAVA's commercial position within a competitive anti-VEGF market. The key developments to watch will include the timing and scale of the US rollout, payer coverage, physician adoption and the company's ability to build a high-performing specialist retina team. Progress across Europe and the UK will also offer early insight into how the treatment is being integrated into established wet AMD pathways. For Outlook Therapeutics, the challenge has now moved decisively from regulatory approval to execution, turning FDA clearance into meaningful market adoption across the US and beyond. For the retina sector, LYTENAVA introduces a new FDA-approved ophthalmic bevacizumab option that could reshape established wet AMD treatment dynamics and competitive expectations.